Related Experiment Video
Updated: May 22, 2026
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer
Karen A Autio1, Howard I Scher, Michael J Morris
1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Opinion Statement:
Skeletal metastases threaten quality of life, functionality, and longevity in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapeutic strategies for bone metastases in prostate cancer can palliate pain, delay/prevent skeletal complications, and prolong survival. Pharmacologic agents representing several drug classes have demonstrated the ability to achieve these treatment goals in men with mCRPC. Skeletal-related events such as fracture and the need for radiation can be delayed using drugs that target the osteoclast/osteoblast pathway. Cancer-related bone pain can be palliated using beta-emitting bone-seeking radiopharmaceuticals such as samarium-153 EDTMP and strontium-89. Also, prospective randomized studies have demonstrated that cytotoxic chemotherapy can palliate bone pain. For the first time, bone-directed therapy has been shown to prolong survival using the novel alpha-emitting radiopharmaceutical radium-223. Given these multifold clinical benefits, treatments targeting bone metabolism, tumor-bone stromal interactions, and bone metastases themselves are now central elements of routine clinical care. Decisions about which agents, alone or in combination, will best serve the patient's and clinician's clinical goals is contingent on the treatment history to date, present disease manifestations, and symptomatology. Clinical trials exploring novel agents such as those targeting c-Met and Src are under way, using endpoints that directly address how patients feel, function, and survive.
Insights
Treatments for bone metastases in prostate cancer improve patient quality of life and survival. Novel therapies like radium-223 prolong survival, making bone-directed treatments essential for metastatic castration-resistant prostate cancer care.
Area of Science:
- Oncology
- Bone Metastasis Research
- Prostate Cancer Therapeutics
Background:
- Skeletal metastases significantly impact quality of life, function, and survival in metastatic castration-resistant prostate cancer (mCRPC).
- Effective therapeutic strategies are crucial for managing bone metastases, aiming to alleviate pain, prevent skeletal complications, and extend survival.
Purpose of the Study:
- To review current and emerging therapeutic strategies for managing bone metastases in prostate cancer.
- To highlight the role of bone-directed therapies in improving patient outcomes, including survival.
Main Methods:
- Review of pharmacologic agents targeting osteoclast/osteoblast pathways.
- Evaluation of radiopharmaceuticals (e.g., samarium-153 EDTMP, strontium-89, radium-223) for pain palliation and survival benefit.
- Consideration of cytotoxic chemotherapy for pain management.
- Discussion of novel agents targeting c-Met and Src.
Main Results:
- Pharmacologic agents and radiopharmaceuticals can effectively palliate pain and delay skeletal-related events.
- Radium-223, an alpha-emitting radiopharmaceutical, has demonstrated the ability to prolong survival in mCRPC patients.
- Bone-directed therapies are integral to the routine clinical management of prostate cancer with bone metastases.
Conclusions:
- Bone-directed therapies offer significant clinical benefits, including pain relief, prevention of skeletal complications, and prolonged survival.
- Treatment decisions should be individualized based on patient history, disease presentation, and symptoms.
- Ongoing clinical trials are investigating novel agents to further improve patient function, well-being, and survival.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...